Unchanged serum levels of advanced glycation endproducts in patients with liver disease

Author： Butscheid Moritz   Schäfer Christian   Brenner Stefanie   Alscher Dominik   Mürdter Thomas   Niwa Toshimitsu   Frischmann Matthias   Pischetsrieder Monika   Klotz Ulrich  

Publisher： Springer Publishing Company

ISSN： 0028-1298

Source： Naunyn-Schmiedeberg's Archives of Pharmacology, Vol.375, Iss.6, 2007-08, pp. : 401-406

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Angiotensin-Converting Enzyme Inhibition Influences Serum Levels of Advanced Glycation End Products in Patients with Coronary Artery Disease: Results from a HOPE Substudy

By  

Heart Drug, Vol. 3, Iss. 2, 2003-08 ,pp. : 67-72

Karger

Access to resources Recommend Favorite

Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimer's Disease

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 4, Iss. 3, 2005-06 ,pp. : 249-266

Bentham Science Publishers

Access to resources Recommend Favorite

Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 973-978

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation Endproducts and Diabetes. Beyond Vascular Complications

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 2, 2011-06 ,pp. : 132-140

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 969-972

Bentham Science Publishers

Access to resources Recommend Favorite